Join Growin Stock Community!
Beta
Back to RIGL.US Analysis

Ticker

Value

empty

There is no following symbol in this watchlist.

  • EPS
  • EPS Diluted
  • Revenue
  • Operation Income
  • Net Income
  • Operating Expenses
  • Cash Flow
  • Cash & Debt
  • Current Contract Liabilities
revenue-chart

RIGL Revenue

This disclaimer is provided by TradingValley Inc. and includes any messages, news, research, analysis, prices or other information provided by the Company's website, the application "Growin App" and other services provided through the Company's website. It is only general market information for educational and investment decision-making reference, and does not constitute any investment advice. View Growin Disclaimer

Rigel pharmaceuticals, inc. (RIGL) 2026Q1 financial report shows revenue of 58.82M USD, with a YoY growth rate of 10.28%. This figure indicates that Rigel pharmaceuticals, inc. (RIGL)’s operational performance has remained fundamentally stable. The moderate growth rate reflects a relatively steady market environment. Investors are advised to continuously and closely monitor the company’s future quarterly financial performance and key strategic adjustments. For a more comprehensive and objective assessment of Rigel pharmaceuticals, inc. (RIGL)’s future growth potential and investment opportunities, it is recommended to incorporate Growin AI Value Analysis for a thorough and prudent evaluation.